Search

Author/Creator Caers, J.

3. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. (8th April 2019)

Authors:
Bringhen, S.; Milan, A.; D'Agostino, M.; Ferri, C.; Wäsch, R.; Gay, F.; Larocca, A.; Offidani, M.; Zweegman, S.; Terpos, E.; Goldschmidt, H.; Cavo, M.; Ludwig, H.; Driessen, C.; Auner, H. W.; Caers, J.; Gramatzki, M.; Dimopoulos, M. A.; Boccadoro, M.; Einsele, H.
Journal:
Journal of internal medicine
Issue:
Volume 286:Number 1(2019)
Page Start:
63
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. S170: DYNAMIC INTERPLAY BETWEEN TUMOR AND MICRO-ENVIRONMENT DURING MYELOMA DISEASE PROGRESSION. (23rd June 2022)

Authors:
Köse, M. C.; Bergiers, I.; Malfait, M.; Heidrich, B.; De Maeyer, D.; Fourneau, N.; Verbist, B.; Van Houdt, J.; Vanhoof, G.; Verona, R.; Delforge, M.; Depaus, J.; Meuleman, N.; Van Droogenbroeck, J.; Vlummens, P.; Heuck, C. J.; Bahlis, N.; Caers, J.; Casneuf, T.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
71
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. S182: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED EFFICACY AND SAFETY RESULTS FROM MONUMENTAL-1. (23rd June 2022)

Authors:
Minnema, M. C.; Krishnan, A.; Berdeja, J. G.; Oriol, A.; van de Donk, N. W.; Rodríguez-Otero, P.; Morillo, D.; Mateos, M.-V.; Costa, L. J.; Caers, J.; Vishwamitra, D.; Ma, J.; Yang, S.; Hilder, B. W.; Tolbert, J.; Goldberg, J. D.; Chari, A.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
83
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗